Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
ObjectiveThe International Guideline Harmonization Group recommended childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the risk of hearing loss. We assessed awareness among adult CCS.MethodsWe identified adults diagnosed with cancer <20 years who had received ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and invited them to the HEAR-study. Participants completed a questionnaire and underwent pure-tone audiometry. Cancer and treatment data came from the ChCR. We used logistic regression to explore factors influencing awareness.Results105 of 424 invited CCS participated (25%). 57% did not remember receiving information on hearing loss prior to the study. CCS who remembered being informed were more likely diagnosed after 1995 (OR: 4.5, 95% CI: 1.3-15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus cranial radiotherapy only. 44% of participants had clinically relevant hearing loss according to SIOP-Boston ototoxicity scale.ConclusionsOver half of CCS exposed to ototoxic treatments were unaware of their risk of hearing loss.Practice ImplicationsEducating CCS about potential late effects of ototoxic treatments is important to allow early diagnosis and treatment, especially for those who had cancer longer ago and those exposed to cranial radiation.HighlightsHalf of CCS exposed to ototoxic treatment were unaware of the risk of hearing loss (85/85)CCS treated before 1995 were less often informed about the risk of hearing loss (84/85)Information provision is key to effective monitoring and early intervention (77/85)
ObjectiveThe International Guideline Harmonization Group recommended childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the risk of hearing loss. We assessed awareness among adult CCS.MethodsWe identified adults diagnosed with cancer <20 years who had received ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and invited them to the HEAR-study. Participants completed a questionnaire and underwent pure-tone audiometry. Cancer and treatment data came from the ChCR. We used logistic regression to explore factors influencing awareness.Results105 of 424 invited CCS participated (25%). 57% did not remember receiving information on hearing loss prior to the study. CCS who remembered being informed were more likely diagnosed after 1995 (OR: 4.5, 95% CI: 1.3-15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus cranial radiotherapy only. 44% of participants had clinically relevant hearing loss according to SIOP-Boston ototoxicity scale.ConclusionsOver half of CCS exposed to ototoxic treatments were unaware of their risk of hearing loss.Practice ImplicationsEducating CCS about potential late effects of ototoxic treatments is important to allow early diagnosis and treatment, especially for those who had cancer longer ago and those exposed to cranial radiation.HighlightsHalf of CCS exposed to ototoxic treatment were unaware of the risk of hearing loss (85/85)CCS treated before 1995 were less often informed about the risk of hearing loss (84/85)Information provision is key to effective monitoring and early intervention (77/85)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.